LINC00852: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

Target Name: LINC00852

NCBI ID: G84657

LINC00852

LINC00852: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

Introduction

LINC00852 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It is characterized by its unique 3'-end overlapping sequence, which consists of a poly(A) tail and multiple domains . LINC00852 plays an important role in biological processes such as gene expression regulation, RNA-binding protein (RBP) interaction, and RNA splicing. In addition, LINC00852 may also be studied as a drug target or biomarker. This article will review the structure, function, drug targets and biomarker research of LINC00852.

Structure and Function

LINC00852 is a non-coding RNA molecule approximately 290 nucleotides in length. It consists of an open reading frame (ORF) that includes a poly(A) tail and multiple domains. The poly(A) tail is a special structure in RNA molecules, consisting of multiple nucleotide units, and is mainly involved in the stability of RNA. Multiple domains include a conserved 伪-helix, a conserved 尾-sheet, and a novel open region that contains a glycosylation-modified binding site that may bind to the protein.

LINC00852 plays an important role in the regulation of gene expression. Research shows that LINC00852 is involved in gene expression and regulation in a variety of biological processes, such as cell proliferation, differentiation, and tumor formation. In addition, LINC00852 is also involved in RNA-binding protein (RBP) interaction, which is an important gene expression regulatory mechanism. RBPs are proteins composed of a subfamily of RNA-binding proteins that regulate gene expression by binding to DNA or RNA molecules. The RBP binding site of LINC00852 is located between its conserved 伪-helix and 尾-sheet. This is an important binding site. After binding to RBP, it can affect the stability, binding affinity and binding efficiency of the conjugate.

as a drug target

Research on LINC00852 as a drug target is of high value. In the process of drug research and development, the discovery and screening of new drug targets is an important link. As a non-coding RNA molecule, LINC00852 is considered a potential drug target due to its unique structure and function. Currently, LINC00852 has been used in target research for a variety of drugs, including the treatment of cancer, neurodegenerative diseases, immune regulation and other diseases.

as biomarkers

LINC00852 can also be studied as a biomarker. Biomarkers are molecules that can be used to detect and evaluate a specific physiological or disease state. LINC00852 plays an important role in a variety of biological processes and is therefore considered a potential biomarker. Currently, LINC00852 has been used in the diagnosis and treatment of a variety of diseases, such as cancer, neurodegenerative diseases, and immune regulation.

Conclusion

LINC00852 is a long non-coding RNA molecule with unique structure and function. It plays an important role in biological processes such as gene expression regulation, RNA-binding protein (RBP) interaction and RNA splicing. In addition, LINC00852 also has the potential to be studied as a drug target or biomarker. In the future, with the continuous advancement of technology, LINC00852 will play a more important role in drug research and development and disease diagnosis and treatment.

Protein Name: Long Intergenic Non-protein Coding RNA 852

The "LINC00852 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00852 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets